Literature DB >> 9790399

Fatty acid desaturase activities and polyunsaturated fatty acid composition in human liver between the seventeenth and thirty-sixth gestational weeks.

A Rodriguez1, P Sarda, C Nessmann, P Boulot, J P Poisson, C L Leger, B Descomps.   

Abstract

OBJECTIVE: The aim of the study was to characterize n-3 and n-6 fatty acid delta5- and delta6-desaturase activities and their time course variations in human fetal liver between the 17th and 36th gestational week. STUDY
DESIGN: Twenty-one biologic samples were obtained after legally approved medical abortion, according to French law. The desaturase activities were measured in the 21 liver samples by a radiochemical method by means of reverse-phase high-performance liquid chromatography. The fatty acid composition (percentage by weight) of liver phospholipids was assessed in 16 samples by gas-liquid chromatographic analysis.
RESULTS: Both delta5- and delta6-desaturase activities were significantly expressed between the 17th and 36th gestational weeks. During the second trimester n-6 fatty acid delta5- and delta6-desaturase activities showed opposite patterns of variation; both then remained stable between the 25th and 36th weeks. Delta6-desaturation was higher in n-3 than n-6 fatty acids and peaked at the 18th gestational week. The percentages of linoleic and docosahexaenoic acids in liver microsomes were positively correlated with the gestation age (P < .01), whereas arachidonic acid remained stable.
CONCLUSION: Significant n-3 and n-6 delta5- and delta6-desaturase activities are expressed in human fetal liver as early as the 17th gestational week and are stable throughout the third trimester. Their theoretic capacity evaluated from in vitro measurements appears lower than polyunsaturated fatty acid requirements and is not directly related to liver microsomal membrane fatty acid composition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790399     DOI: 10.1016/s0002-9378(98)70216-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  The composition of saturated fatty acids in plasma phospholipids changes in a way to counteract changes in the mean melting point during pregnancy.

Authors:  S R De Vriese; A C Houwelingen; G Hornstra; M Dhont; A B Christophe
Journal:  Lipids       Date:  2001-01       Impact factor: 1.880

2.  Differential effect of N-ethyl maleimide on delta6-desaturase activity in human fetal liver toward fatty acids of the n-6 and n-3 series.

Authors:  A Rodriguez; P Sarda; P Boulot; C L Leger; B Descomps
Journal:  Lipids       Date:  1999-01       Impact factor: 1.880

3.  Both maternal and offspring Elovl2 genotypes determine systemic DHA levels in perinatal mice.

Authors:  Anna M Pauter; Sofia Trattner; Amanda Gonzalez-Bengtsson; Emanuela Talamonti; Abolfazl Asadi; Olga Dethlefsen; Anders Jacobsson
Journal:  J Lipid Res       Date:  2016-11-18       Impact factor: 5.922

4.  Maternal and child fatty acid desaturase genotype as determinants of cord blood long-chain PUFA (LCPUFA) concentrations in the Seychelles Child Development Study.

Authors:  Marie C Conway; Emeir M McSorley; Maria S Mulhern; Toni Spence; Maria Weslowska; J J Strain; Edwin van Wijngaarden; Phil W Davidson; Gary J Myers; Karin E Wahlberg; Conrad F Shamlaye; Diego F Cobice; Barry W Hyland; Daniela Pineda; Karin Broberg; Alison J Yeates
Journal:  Br J Nutr       Date:  2021-02-02       Impact factor: 3.718

5.  Umbilical cord PUFA are determined by maternal and child fatty acid desaturase (FADS) genetic variants in the Avon Longitudinal Study of Parents and Children (ALSPAC).

Authors:  Eva Lattka; Berthold Koletzko; Sonja Zeilinger; Joseph R Hibbeln; Norman Klopp; Susan M Ring; Colin D Steer
Journal:  Br J Nutr       Date:  2012-08-09       Impact factor: 3.718

Review 6.  Is there A Role for Alpha-Linolenic Acid in the Fetal Programming of Health?

Authors:  Alicia I Leikin-Frenkel
Journal:  J Clin Med       Date:  2016-03-23       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.